The association of D-dimer levels with other prognostic factors in patients with lung cancer

Turkish Journal of Medical Sciences

Volumn 38, Issue 3, 2008, Pages 209-217

  Inal, Satilmiş ^a   Taşçi, Cantürk ^a   Karadurmuş, Nuri ^a   Kuzhan, Okan ^a   Balkan, Arzu ^a   Özkan, Metin ^a   Bilgiç, Hayati ^a   Özet, Ahmet ^a   Ekiz, Kudret ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

D dimer; Lung cancer

Indexed keywords

COAGULATION; DRUG PRODUCTS; FLOCCULATION; HEALTH; PATIENT MONITORING; PIGMENTS; POLYSACCHARIDES;

(E ,3E) PROCESS; DEEP VENOUS THROMBOSIS (DVT); HISTOPATHOLOGICAL TYPE; INITIATION (ELECTRIC DISCHARGES); LOW MOLECULAR WEIGHT HEPARIN (LMWH); LUNG CANCERS; PERFORMANCE STATUS (PS); PROGNOSTIC FACTORS; RISK FACTORS; SURVIVAL TIME; THROMBOEMBOLISM (TE); TO EFFECT;

BIOLOGICAL ORGANS;

ANTICOAGULANT AGENT; D DIMER; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PROGNOSIS; RISK FACTOR; THROMBOEMBOLISM;

EID: 45749107923     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Khorana AA. Malignancy, thrombosis and trousseau: the case for an eponym. J. Thromb. Heamost. 2003;1(12):2463-5.
2. Freyburger G, Trillaud H, Labrouche S, Gauther P, Javorschi S, Bernard P et all. D-dimer strategy in thrombosis exclusion - a gold standard study in 100 patients suspected of deep venous thrombosis or pulmonary embolism: 8 DD methods compared. Thromb Haemost 1998; 79(1):32-7.
3. Weiner SG, Burstein JL. Nonspecific tests for pulmonary embolism. Emergency Medicine Clinics of North America 2003; 19 (4): 943-955.
4. Bayes-Genis A, Mateo J, Santalo M, Oliver A, Guindo J. Badimon L et all. D-dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. American Heart Journal 2000, 140 (3): 379-384.
5. Chabloz P, Reber G, Boehlen F, Hohlfeld P, De Moerloose P. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. British Journal of Haematology 2001; 115:150-152.
6. Bovill EG, Tracy RP. Fibrinogen degradation products. In: Beuller, E., Lichman, M.A., Coller, B.S., Kipps, T.J ed. William's Haematology. New York: Mc Graw-Hill; 1995, p104-105.
7. Boisclair MD, Lane DA, Wilde JT, Ireland H, Preston FE, Ofosu FA. A comparative evaluation of assay for markers of activated coagulation and/or fibrinolysis: Thrombin-antithrombin Complex, D-dimer and Fibrinogen/Fibrin Fragment E Antigen.: Br J Haematol. 1990 Apr;74(4):471-9.
8. Lowe GDO. Fibrinogen. A Cardiovascular Risk Factor. Mannheim: Boehringer Mannheim:1997.
9. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: Clinical and Prognostic Significance. Cancer 2003; 97(12):3044-52.
10. Unsal E, Atalay F, Atikcan S, Y?lmaz A. Prognostic significance of hemostatic parameters in patients with lung cancer. Respi. Med. 2004; 98(2): 93-8.
11. Shen VS, Pollak EW. Fatal Pulmonary Embolism in Cancer Patients. Is Heparin Prophlaxis Justified ? South Med J 1980; 73: 841-43.
12. Taguchi O., Gabazza EC, Yasui H, Kobayashi T, Yoshida M.,Kobayashi H. Prognostic Significance of Plasma D-dimer Levels in Patients with Lung Cancer. Thorax 1997, 52: 563-565.
13. Kelly J, Rudd A, Lewis RR, Hunt B. J. Plasma D-dimer in Diagnosis of Venous Thromboembolism. Arch. of Int. Med 2002; 162: 747-756.